| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,860 | 0,920 | 23:00 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PROMIMIC Aktie jetzt für 0€ handeln | |||||
| 20.08. | Promimic AB Q2 Sales Increase | 1 | RTTNews |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 78,44 | +2,24 % | Medtronic Announces Regulatory Milestones For Cardiac Mapping Software | WASHINGTON (dpa-AFX) - Wednesday, Medtronic plc (MDT) said it received FDA clearance and CE Mark for the latest Affera Prism-2 Mapping Software and CE Mark for the PulseSelect ProxBox Adapter... ► Artikel lesen | |
| HCA HEALTHCARE | 382,70 | +0,92 % | Cantor Fitzgerald reiterates HCA Healthcare stock Overweight rating | ||
| LANTHEUS | 89,40 | +0,56 % | Laufende Fusionskontrollverfahren: Curium US Holdings LLC, Boston, MA/USA (Fonds der Cap Vest Partners); Erwerb sämtlicher Anteile an und Kontrolle über Lantheus Holdings, Inc., Bedford, MA/USA | Datum der Anmeldung:25.09.2026Aktenzeichen:B3-104/26Unternehmen:Curium US Holdings LLC, Boston, MA/USA (Fonds der Cap Vest Partners); Erwerb sämtlicher Anteile an und Kontrolle über Lantheus Holdings... ► Artikel lesen | |
| CAREDX | 63,00 | +5,00 % | Biotech Stocks At 52-Week Highs - CareDx +13%, Grail Inc. +15%, Twist Bioscience +16%, Adaptive Biotechnologies, Revvity | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on September 24, 2026, driven by key catalysts such as reaching certain regulatory milestones or results from clinical... ► Artikel lesen | |
| ENVISTA | 20,800 | 0,00 % | Leaner Operations and Improving Dental Demand Position Envista Holdings Corp. (NVST) for Multi-Year Growth | ||
| GT BIOPHARMA | 6,160 | 0,00 % | GT Biopharma, Inc.: GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma | FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol Initiation of Phase 1 trial in MM patients contingent upon timing and receipt... ► Artikel lesen | |
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports Fourth Quarter and Fiscal Year 2026 Results | Reports Record Fiscal Year Net Income of $2.8 Million, 14% YoY B2B ARR Increase and ARR of $22.5 Million
HENDERSON, Nev., Sept. 9, 2026 /PRNewswire/ -- Research... ► Artikel lesen | |
| CARMAT | - | - | CARMAT SAS: EFICAS Study Results Confirm the Clinical Performance of the Aeson Total Artificial Heart as a Bridge-to-Transplant Therapy | The study's primary endpoint was achieved in 72.7% of the 55 patients implanted between December 2022 and May 2025.
This rate was significantly above the historical benchmark of 38% established... ► Artikel lesen | |
| CHEMOMETEC | 78,45 | +6,44 % | Chemometec A/S: Upgrade of revenue and operating profit guidance | ANNOUNCEMENT NO. 3175 October 2026 ChemoMetec maintained its positive momentum in the first quarter of the 2026/27 financial year, supported by higher-than-expected demand for our instruments, with... ► Artikel lesen | |
| POLAREAN IMAGING | 0,002 | 0,00 % | Polarean: Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026 | ||
| DEVYSER DIAGNOSTICS | 4,670 | -1,68 % | Devyser Diagnostics AB: Devyser appoints Torben Thölix as the new Chief Commercial Officer | Devyser today announces the appointment of Torben Thölix as Chief Commercial Officer (CCO). Torben will lead Devyser's global commercial organization and join the executive management team, reporting... ► Artikel lesen | |
| ARRAIL GROUP | 0,203 | -100,00 % | ARRAIL GROUP (06639): FURTHER DELAY IN PUBLICATION OF OUTSTANDING FINANCIAL RESULTS AND POSTPONEMENT OF ANNUAL GENERAL MEETING AND CONTINUED SUSPENSION ... | ||
| FRESENIUS | 43,865 | -0,38 % | Fresenius Kabi erhält Warnung von der US-Gesundheitsbehörde FDA | DJ Fresenius Kabi erhält Warnung von der US-Gesundheitsbehörde FDA
DOW JONES--Die Fresenius-Tochter Kabi hat einen Warnschuss von der US-Gesundheitsbehörde FDA erhalten. In dem am Dienstag veröffentlichten... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 37,450 | +0,66 % | JEFFERIES stuft Siemens Healthineers auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Siemens Healthineers mit einem Kursziel von 50 Euro auf "Buy" belassen. Accela sei ein Quantensprung in der Strahlentherapie... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,250 | -0,33 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen |